About

Innoblative Designs, Inc:

Innoblative, a private medical device company addressing clinical unmet needs for patients with breast cancer and other soft tissue disease, received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the company's SIRA™ RFA Electrosurgical Device (SIRA). The SIRA device is intended for use in breast cancer patients undergoing BCS, commonly referred to as lumpectomy. Innoblative's SIRA™ device has a unique spherical shape to the entire cavity that circumferentially delivers RF energy and yields reproducible ablation depths to provide greater confidence of a consistent thermal effect.